Market Overview

UPDATE: Bank of America Raises PO to $130 on Alexion Pharmaceuticals on Soliris Data

Related ALXN
Benzinga's Top Upgrades
Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant
Stocks Climb As Biotechs Rebound; Tesla Slips On Shift Into Neutral (Investor's Business Daily)

Bank of America reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) and raised its price objective from $118 to $130.

Bank of America commented, "We are increasing our PO from $118 to $130 to reflect a higher probability of success for Soliris in neuromyelitis optica (NMO) following impressive Phase 2 data presented yesterday. We removed MG and the nondescript "other indications" for Soliris from our valuation, as current data suggests NMO may be the final large indication beyond PNH and aHUS (STEC and AMR incremental drivers)."

Alexion Pharmaceuticals closed at $111.30 on Tuesday.

Latest Ratings for ALXN

Oct 2015Morgan StanleyUpgradesEqual-weightOverweight
Sep 2015BarclaysDowngradesOverweightEqual-weight
Jul 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (ALXN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters